These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16575534)

  • 1. Cystemustine in recurrent high grade glioma.
    Durando X; Thivat E; Roché H; Bay JO; Lemaire JJ; Verrelle P; Chazal J; Curé H; Chollet P
    J Neurooncol; 2006 Aug; 79(1):33-7. PubMed ID: 16575534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.
    Pérez-Segura P; Manneh R; Ceballos I; García A; Benavides M; Fuster J; Vaz MA; Cano JM; Berros JP; Covela M; Moreno V; Quintanar T; García Bueno JM; Fernández I; Sepúlveda J
    Clin Transl Oncol; 2016 Aug; 18(8):805-12. PubMed ID: 26542177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy.
    Rajan B; Ross G; Lim CC; Ashley S; Goode D; Traish D; Brada M
    Eur J Cancer; 1994; 30A(12):1809-15. PubMed ID: 7880611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults.
    Roche H; Cure H; Adenis A; Fargeot P; Terret C; Lentz MA; Madelmont JC; Fumoleau P; Hanausk A; Chollet P
    J Neurooncol; 2000 Sep; 49(2):141-5. PubMed ID: 11206009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of second-line chemotherapy with non-conventional fotemustine schedule in recurrent high grade gliomas: a single institution experience.
    Gaviani P; Simonetti G; Salmaggi A; Lamperti E; Silvani A
    J Neurooncol; 2013 Jul; 113(3):527-9. PubMed ID: 23703296
    [No Abstract]   [Full Text] [Related]  

  • 6. Temozolomide in the treatment of recurrent malignant glioma.
    Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
    Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of malignant recurrent glioma by intra-arterial, infra-ophthalmic infusion of HECNU 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl) urea. A phase II study.
    Poisson M; Chiras J; Fauchon F; Debussche C; Delattre JY
    J Neurooncol; 1990 Jun; 8(3):255-62. PubMed ID: 2193122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of the association of a methionine-free diet with cystemustine therapy in melanoma and glioma.
    Thivat E; Farges MC; Bacin F; D'Incan M; Mouret-Reynier MA; Cellarier E; Madelmont JC; Vasson MP; Chollet P; Durando X
    Anticancer Res; 2009 Dec; 29(12):5235-40. PubMed ID: 20044642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.
    Nagpal S; Recht CK; Bertrand S; Thomas RP; Ajlan A; Pena J; Gershon M; Coffey G; Kunz PL; Li G; Recht LD
    J Neurooncol; 2015 Jun; 123(2):277-82. PubMed ID: 25935109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective study of nivolumab for patients with recurrent high grade gliomas.
    Mantica M; Pritchard A; Lieberman F; Drappatz J
    J Neurooncol; 2018 Sep; 139(3):625-631. PubMed ID: 29779086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas.
    Yao H; Liu J; Zhang C; Shao Y; Li X; Feng M; Wang X; Gan W; Zhou Y; Huang Y
    J Clin Neurosci; 2021 Aug; 90():82-88. PubMed ID: 34275586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results.
    Galanis E; Buckner JC; Burch PA; Schaefer PL; Dinapoli RP; Novotny PJ; Scheithauer BW; Rowland KM; Vukov AM; Mailliard JA; Morton RF
    J Clin Oncol; 1998 Sep; 16(9):2953-8. PubMed ID: 9738563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
    Duerinck J; Du Four S; Sander W; Van Binst AM; Everaert H; Michotte A; Hau P; Neyns B
    Anticancer Res; 2015 Oct; 35(10):5551-7. PubMed ID: 26408725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma.
    Pace A; Mandoj C; Antenucci A; Villani V; Sperduti I; Casini B; Carosi M; Fabi A; Vidiri A; Koudriavtseva T; Conti L
    J Neurooncol; 2018 Jul; 138(3):527-535. PubMed ID: 29594657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
    Raymond E; Brandes AA; Dittrich C; Fumoleau P; Coudert B; Clement PM; Frenay M; Rampling R; Stupp R; Kros JM; Heinrich MC; Gorlia T; Lacombe D; van den Bent MJ;
    J Clin Oncol; 2008 Oct; 26(28):4659-65. PubMed ID: 18824712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin chemotherapy in patients with recurrent high-grade glioma.
    Murray LJ; Bridgewater CH; Levy D
    Clin Oncol (R Coll Radiol); 2011 Feb; 23(1):55-61. PubMed ID: 20952169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCNU treatment for recurrent malignant gliomas.
    Levin VA; Resser KJ; McGrath L; Vestnys P; Nutik S; Wilson CB
    Cancer Treat Rep; 1984; 68(7-8):969-73. PubMed ID: 6744348
    [No Abstract]   [Full Text] [Related]  

  • 18. Platinum-based chemotherapy in recurrent high-grade glioma patients: retrospective study.
    Roci E; Cakani B; Brace G; Bushati T; Rroji A; Petrela M; Kaloshi G
    Med Arch; 2014; 68(2):140-3. PubMed ID: 24937942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of fotemustine in recurrent supratentorial malignant gliomas.
    Frenay M; Giroux B; Khoury S; Derlon JM; Namer M
    Eur J Cancer; 1991; 27(7):852-6. PubMed ID: 1834116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
    Prados MD; Lamborn K; Yung WK; Jaeckle K; Robins HI; Mehta M; Fine HA; Wen PY; Cloughesy T; Chang S; Nicholas MK; Schiff D; Greenberg H; Junck L; Fink K; Hess K; Kuhn J;
    Neuro Oncol; 2006 Apr; 8(2):189-93. PubMed ID: 16533878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.